DK200000792A - Lindring af Peyronie's sygdom - Google Patents
Lindring af Peyronie's sygdom Download PDFInfo
- Publication number
- DK200000792A DK200000792A DK200000792A DKPA200000792A DK200000792A DK 200000792 A DK200000792 A DK 200000792A DK 200000792 A DK200000792 A DK 200000792A DK PA200000792 A DKPA200000792 A DK PA200000792A DK 200000792 A DK200000792 A DK 200000792A
- Authority
- DK
- Denmark
- Prior art keywords
- collagenase
- approx
- pharmaceutical composition
- peyronie
- disease
- Prior art date
Links
- 208000004362 Penile Induration Diseases 0.000 title description 4
- 208000020758 Peyronie disease Diseases 0.000 title description 4
- 102000029816 Collagenase Human genes 0.000 description 16
- 108060005980 Collagenase Proteins 0.000 description 16
- 229960002424 collagenase Drugs 0.000 description 16
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 3
- 239000008365 aqueous carrier Substances 0.000 description 2
- 238000005452 bending Methods 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
PATENTKRAV 1. Anvendelse af collagenase til fremstilling af et farmaceutisk præparat til behandling af Peyronie's sygdom ved injektion af det farmaceutiske præparat i en fibrøs Peyronie's plak i penisen på et individ, som lider af sygdommen, hvorved det farmaceutiske præparat injiceres på en sådan måde, at det tilvejebringer en collagenase-mængde og -koncentration, som er i stand til at blødgøre og/eller bryde hul på plakken, idet penisen immobiliseres umiddelbart efter injektionen og fastholdes immobil i adskillige timer, hvorved den penile bøjning, der er forårsaget af plakken, tindres. 2. Anvendelse ifølge krav 1, ved hvilken det farmaceutiske præparat indeholder collagenase i en koncentration på ca. 20.000 til ca. 40.000 ABC-enheder pr. ml i en farmaceutisk acceptabel bærer, og den injicerede mængde indeholder mindst ca. 20.000 ABC-enheder collagenase. 3. Anvendelse ifølge krav 2, ved hvilken den maksimale akkumulerede samlede dosis ikke overstiger ca. 60.000 ABC-enheder collagenase. 4. Anvendelse ifølge et hvilket som helst af kravene 1 til 3, ved hvilken immobiliseringsperioden er fra ca. 4 til ca. 12 timer. 5. Anvendelse ifølge et hvilket som helst af kravene 1-4, ved hvilken det farmaceutiske præparat omfatter collagenase i en vandig bærer. 6. Farmaceutisk præparat til behandlingen af Peyronie's sygdom omfattende en farmaceutisk virkningsfuld collagenase-mængde og -koncentration og en farmaceutisk acceptabel bærer. 7. Farmaceutisk præparat til behandling af et individ, der lider af Peyronie's sygdom, omfattende en virkningsfuld collagenase-mængde og -koncentration af til en serie på mindst to injektioner på hver mindst 10.000 ABC-enheder collagenase, som indgives med mindst én dags mellemrum, og tilvejebringer en samlet mængde på mindst ca. 20.000 ABC-enheder collagenase, hvor omtalte mængde og koncentration er i stand til at blødgøre og/eller bryde hul på plakken, hvorved den penile bøjning, der er forårsaget af plakken, lindres. 8. Farmaceutisk præparat ifølge krav 7, omfattende ca. 10.000 til ca. 20.000 ABC-enheder collagenase til hver injektion. 9. Farmaceutisk præparat ifølge et hvilket som helst af krav 7 eller 8 omfattende collagenase i en koncentration på ca. 20.000 til ca. 40.000 ABC-enheder pr. ml i en farmaceutisk acceptabel bærer. 10. Farmaceutisk præparat ifølge et hvilket som helst af kravene 7 til 9 til en serie på ca. ugentlige injektioner hver omfattende ca. 10.000 til ca. 20.000 ABC-enheder collagenase, og ikke overskridende en maksimal akkumuleret samlet dosis på ca. 60.000 ABC-enheder collagenase. 11. Farmaceutisk præparat ifølge et hvilket som helst af kravene 7 til 10 omfattende collagenase og en vandig bærer. 12. Farmaceutisk præparat ifølge et hvilket som helst af kravene 6 til 11, hvori omtalte collagenase er på en enhedsdosisform.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32522499 | 1999-06-03 | ||
| US09/325,224 US6022539A (en) | 1999-06-03 | 1999-06-03 | Amelioration of peyronie's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK200000792A true DK200000792A (da) | 2000-12-04 |
| DK177177B1 DK177177B1 (da) | 2012-04-30 |
Family
ID=23266961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DKPA200000792A DK177177B1 (da) | 1999-06-03 | 2000-05-16 | Lindring af Peyronie's sygdom |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6022539A (da) |
| AU (1) | AU3532900A (da) |
| CA (1) | CA2308842C (da) |
| DE (1) | DE10027521A1 (da) |
| DK (1) | DK177177B1 (da) |
| FR (1) | FR2794369B1 (da) |
| GB (1) | GB2352173B (da) |
| NO (1) | NO333945B1 (da) |
| SE (1) | SE0001914L (da) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2197018B1 (es) * | 2002-06-06 | 2005-10-01 | Especialidades Farmaceuticas Centrum Sa | Nuevo uso terapeutico de los extractos de polypodium. |
| US20070224184A1 (en) * | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
| HUE027236T2 (en) * | 2005-01-21 | 2016-10-28 | The Res Found Of State Univ Of New York | Methods for Adhesive Capsulitis Treatment |
| US7811560B2 (en) | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
| US8323642B2 (en) * | 2006-12-13 | 2012-12-04 | Depuy Mitek, Inc. | Tissue fusion method using collagenase for repair of soft tissue |
| US20080233614A1 (en) * | 2007-02-13 | 2008-09-25 | Cranenburgh Rocky M | Production of recombinant collagenases colg and colh in escherichia coli |
| US10071143B1 (en) | 2007-05-03 | 2018-09-11 | The Research Foundation For The State University Of New York | Methods for non-surgical treatment of carpal tunnel syndrome |
| US20100159564A1 (en) * | 2007-11-30 | 2010-06-24 | Dwulet Francis E | Protease resistant recombinant bacterial collagenases |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| US20100061972A1 (en) * | 2008-08-19 | 2010-03-11 | Auxilium US Holdings,LLC | Method of Treating Peyronie's Disease |
| WO2010102262A1 (en) | 2009-03-06 | 2010-09-10 | Halozyme, Inc. | Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof |
| US8465413B2 (en) | 2010-11-25 | 2013-06-18 | Coloplast A/S | Method of treating Peyronie's disease |
| US9180172B2 (en) | 2010-12-15 | 2015-11-10 | Ams Research Corporation | Treatment of Peyronies disease |
| WO2012125948A1 (en) | 2011-03-16 | 2012-09-20 | Biospecifics Technologies Corp. | Compositions and methods for producing clostridial collagenases |
| JP6049714B2 (ja) | 2011-07-20 | 2016-12-21 | メディウンド リミテッド | 結合組織疾患の治療のためのブロメライン由来タンパク質分解抽出物 |
| NZ750379A (en) | 2012-01-12 | 2022-10-28 | Auxilium Int Holdings Inc | Clostridium histolyticum enzymes and methods for the use thereof |
| US20180028575A1 (en) | 2012-01-30 | 2018-02-01 | Michael Zahalsky | Methods and compositions for treatment of penile defects |
| WO2013116327A1 (en) * | 2012-01-30 | 2013-08-08 | Zahalsky Michael P | Methods and compositions for treatment of penile defects |
| WO2014107745A1 (en) | 2013-01-07 | 2014-07-10 | Halozyme, Inc. | Metal sensitive mutants of matrix metalloproteases and uses thereof |
| ES2855423T3 (es) | 2013-03-15 | 2021-09-23 | Biospecifics Tech Corporation | Método de tratamiento y producto para fibromas uterinos que utiliza colagenasa purificada |
| CN103751102A (zh) | 2014-01-15 | 2014-04-30 | 上海交通大学 | 一种胶原酶温敏水凝胶及其制备方法和应用 |
| JP7558654B2 (ja) | 2017-03-01 | 2024-10-01 | エンド ベンチャーズ アンリミテッド カンパニー | セルライトを評価及び処置するための装置及び方法 |
| EP3601556A2 (en) | 2017-03-28 | 2020-02-05 | Endo Ventures Limited | Improved method of producing collagenase |
| US11872267B2 (en) | 2019-10-15 | 2024-01-16 | The Johns Hopkins University | Treatment of uterine fibroids using purified collagenase |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4338300A (en) * | 1981-02-05 | 1982-07-06 | The Regents Of The University Of California | Use of purified clostridial collangenase in the treatment of Peyronie's disease |
| HK1003981A1 (en) * | 1989-01-27 | 1998-11-13 | Immunolytics, Inc. | Composition and method for treating benign prostatic hypertrophy |
| US6086872A (en) * | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
-
1999
- 1999-06-03 US US09/325,224 patent/US6022539A/en not_active Expired - Lifetime
-
2000
- 2000-05-16 AU AU35329/00A patent/AU3532900A/en not_active Abandoned
- 2000-05-16 DK DKPA200000792A patent/DK177177B1/da not_active IP Right Cessation
- 2000-05-19 GB GB0011969A patent/GB2352173B/en not_active Expired - Lifetime
- 2000-05-19 CA CA2308842A patent/CA2308842C/en not_active Expired - Lifetime
- 2000-05-23 SE SE0001914A patent/SE0001914L/ not_active Application Discontinuation
- 2000-05-25 NO NO20002686A patent/NO333945B1/no not_active IP Right Cessation
- 2000-05-29 FR FR0006863A patent/FR2794369B1/fr not_active Expired - Lifetime
- 2000-06-02 DE DE10027521A patent/DE10027521A1/de not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| FR2794369B1 (fr) | 2003-11-21 |
| GB0011969D0 (en) | 2000-07-05 |
| AU3532900A (en) | 2000-12-07 |
| SE0001914L (sv) | 2000-12-04 |
| FR2794369A1 (fr) | 2000-12-08 |
| US6022539A (en) | 2000-02-08 |
| GB2352173A (en) | 2001-01-24 |
| NO20002686D0 (no) | 2000-05-25 |
| NO20002686L (no) | 2000-12-04 |
| DE10027521A1 (de) | 2000-12-07 |
| CA2308842C (en) | 2013-02-12 |
| SE0001914D0 (sv) | 2000-05-23 |
| CA2308842A1 (en) | 2000-12-03 |
| GB2352173B (en) | 2004-11-10 |
| NO333945B1 (no) | 2013-10-28 |
| DK177177B1 (da) | 2012-04-30 |
| IE20000402A1 (en) | 2001-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK200000792A (da) | Lindring af Peyronie's sygdom | |
| CO5261582A1 (es) | Composiciones de valdecoxib | |
| SE0002754D0 (sv) | New pharmaceutical combination formulation and method of treatment with the combination | |
| AU645023B2 (en) | Compositions and method for treating painful, inflammatory or allergic disorders | |
| NO333189B1 (no) | Anvendelse av buprenorfin for fremstilling av en transdermal doseringsform for behandling av medikamentavhengighet, samt sett omfattende slike doseringsformer. | |
| DE59401401D1 (de) | Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit | |
| DE602004018944D1 (de) | Verwendung von abführmittel zur behandlung des reizdarmsyndroms | |
| BR9814280A (pt) | Arilpiperazinas que apresentam atividade noreceptor 1a de serotonina | |
| ATE293451T1 (de) | Behandlung der osteoarthritis durch verabreichung von poly-n-acetyl-d-glucosamin | |
| PT758241E (pt) | Utilizacao de certos derivados de acido metanobisfosfonico para impedir o desprendimento de proteses e a migracao de proteses | |
| DK1255569T3 (da) | Pax2 til behandling af nyresygdomme | |
| IS2259B (is) | Aðferð til meðferðar á netjuhersli með notkun mótlyfs við integríninu alfa-4 undireiningunni | |
| DK0946162T3 (da) | Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme | |
| Bourgeois et al. | Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis | |
| DE60214527D1 (de) | Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit | |
| ATE184484T1 (de) | Wirkstoffe zur behandlung von suchterkrankungen | |
| RU2006139819A (ru) | Применение симетикона для предрасположенных к запорам пациентов | |
| WO1997026880A3 (en) | Use of a combination of delavirdine and one or more protease inhibitors in hiv-1 infected patients | |
| TR200200111T2 (tr) | Neoplazmalar için terapötik ve profilaktik maddeler | |
| RU97115801A (ru) | Способ лечения стенозирующих ларинготрахеитов у детей | |
| FR2786699B1 (fr) | Medicament destine notamment a prevenir ou traiter les dysfonctions sexuelles | |
| FR2818147B1 (fr) | Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine | |
| BR0303384A (pt) | Citalopram e seus usos no tratamento de pressão sanguìnea elevada | |
| RU2000110676A (ru) | Способ консервативного лечения стриктур уретры | |
| DE60020550D1 (de) | Methode und mittel zur behandlung eines post-poliosyndroms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |
Expiry date: 20200516 |